Abstract 4845
Background
Outpatient palliative care (OPC) offers improved symptom control, quality of life and even survival. OPC clinics may be embedded in the oncology clinic or independent. We herein present our experience with an embedded OPC clinic led by a medical oncologist, an internist and a nurse in Hacettepe University Medical Oncology Clinic.
Methods
Patients who were referred by their oncologist or those who had severe symptoms and applied without referral were admitted. Besides baseline history and physical exam, Edmonton Symptom Assesment Scale (ESAS), Nutritional risk screening 2002 and visual analog scale for pain were routinely assessed except for patients with acute symptoms requiring urgent intervention. Interventions and consultations were recorded for all patients.
Results
A total of 174 patients were seen in our clinic within the first 5 months. Demographic features are shown in the table. The chief complaints were pain (26%), nausea and vomiting (13%) and decreased feeding (9%). Besides their chief complaints, patients had a median of 4 (min 0- max 8) other severe (ESAS score of > 5) complaints. The most frequent interventions were intravenous hydration, analgesic and/or antiemetic administration and prescription (n = 66), nutritionist (n = 62) and pain specialist (n = 59) consultations. Thirty-three patients (19 %) were referred for immediate hospitalization. The overall mortality within the first 30 days after the first OPC visit was 17%.Table:
1615P Baseline characteristics of the applied patients
Median Age (minimum- maximum) | 60.5 (17-91) |
Male/Female | 94 (58%)/80 (42%) |
Patient Stages | Stage 1: 4 (2.3%) Stage 2: 7 (4%) Stage 3: 18 (10.3%) Stage 4: 157 (73.6%) |
ECOG Performance Status | ECOG 0: 19 (10.9%) ECOG 1: 50 (28.7%) ECOG 2: 36 (20.7%) ECOG 3: 40 (23%) ECOG 4: 25 (14.4%) |
Tumor Sites | Gastrointestinal: 53 (30.5%) Lung: 43 (24.7%) Genitourinary: 15 (8.6%) Breast: 14 (8%) Gynecologic: 11 (6.3%) Head and Neck Cancer: 9 (5.2%) Other: 29 (16.7%) |
Conclusions
Our initial experience with the embedded OPC clinic mostly included patients with advanced disease, multiple severe symptoms and high risk of mortality. Management of these patients within the oncology clinic may address palliative care needs of these patients, provide timely therapeutic interventions, reduce unnecessary diagnostic tests and diminish emergency department applications by these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5152 - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study
Presenter: Eleonora Bergo
Session: Poster Display session 1
Resources:
Abstract
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract